Neurologic manifestations in hospitalized patients with COVID-19
The ALBACOVID registry
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received May 6, 2020
- Accepted in final form May 22, 2020
- First Published June 1, 2020.
Article Versions
- Previous version (June 1, 2020 - 12:45).
- You are viewing the most recent version of this article.
Author Disclosures
- Carlos Manuel Romero-Sánchez, MD*,
- Inmaculada Díaz-Maroto, MD*,
- Eva Fernández-Díaz, MD*,
- Álvaro Sánchez-Larsen, MD*,
- Almudena Layos-Romero, MD*,
- Jorge García-García, MD,
- Esther González, MD,
- Inmaculada Redondo-Peñas, MD,
- Ana Belén Perona-Moratalla, MD,
- José Antonio Del Valle-Pérez, MD,
- Julia Gracia-Gil, MD,
- Laura Rojas-Bartolomé, MD,
- Inmaculada Feria-Vilar, MD,
- María Monteagudo, MD,
- María Palao, MD,
- Elena Palazón-García, MD,
- Cristian Alcahut-Rodríguez, MD,
- David Sopelana-Garay, MD,
- Yóscar Moreno, MD,
- Javaad Ahmad, MD and
- Tomás Segura, MD, PhD
- Carlos Manuel Romero-Sánchez, MD*,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Inmaculada Díaz-Maroto, MD*,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Eva Fernández-Díaz, MD*,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Álvaro Sánchez-Larsen, MD*,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Almudena Layos-Romero, MD*,
NONE
NONE
(1) Allergan Pharmaceuticals: Funding for travel to speak in a conference (2) Novartis Pharmaceuticals: Funding for travel to conference (3) Lilly Pharmaceuticals: Funding for travel to speak in a conference
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Jorge García-García, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Esther González, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Inmaculada Redondo-Peñas, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ana Belén Perona-Moratalla, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- José Antonio Del Valle-Pérez, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Julia Gracia-Gil, MD,
(1)Biogen (2) Novartis (3) Genzyme (4) Roche
NONE
(1)Biogen (2) Novartis (3) Genzyme (4) Roche
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Laura Rojas-Bartolomé, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Inmaculada Feria-Vilar, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- María Monteagudo, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- María Palao, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Elena Palazón-García, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Cristian Alcahut-Rodríguez, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- David Sopelana-Garay, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Yóscar Moreno, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Javaad Ahmad, MD and
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Tomás Segura, MD, PhD
(1) Amgen Inc(2) Boehringer Ingelheim
NONE
(1) Bayer Pharmaceuticals, funding for travel to conference and speaker honoraria(2) Daiichi-Sankyo Incorp., speaker honoraria
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Proyecto de Investigación en salud. Gobierno de España, Exp: PI18/00466
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Neurology, Complejo Hospitalario Universitario de Albacete, Castilla-La Mancha, Spain.
- Correspondence
Dr. Romero-Sánchez carlosmanuelromerosanchez{at}gmail.com
Article usage
Cited By...
Disputes & Debates: Rapid online correspondence
- Author response: Neurologic manifestations in hospitalized patients with COVID-19: The ALBACOVID registry
- Carlos Manuel Romero-Sánchez, Neurologist, Hospital General de Albacete
Submitted July 15, 2020 - Reader response: Neurologic manifestations in hospitalized patients with COVID-19: The ALBACOVID registry
- Derya Kaya, Neurologist, Dokuz Eylul University Faculty of Medicine,Unit for Brain Aging and Dementia, Department of Geriatric Medicine
- Nuri Karabay, Radiologist, Dokuz Eylul University Faculty of Medicine, Department of Radiology
- Ahmet Turan Isik, Geriatrician, Dokuz Eylul University Faculty of Medicine,Unit for Brain Aging and Dementia, Department of Geriatric Medicine
Submitted July 07, 2020
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.